Logo

Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Share this
Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Insmed's Brensocatib Receives the US FDA's Breakthrough Therapy Designation to Treat Non-Cystic Fibrosis Bronchiectasis

Shots:

  • The BTD is based on P-II WILLOW study assessing brensocatib vs PBO in adults with NCFBE for reducing exacerbations
  • Insmed expects to initiate a P-III program for brensocatib in bronchiectasis in the H2’21
  • Brensocatib is a novel oral- reversible DPP1 inhibitor- currently being developed for the treatment of bronchiectasis and other inflammatory diseases

 ­ Ref: PRNewswire | Image: Twitter

Click here to­ read the full press release 

Tuba

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions